Michael R. McClung

ORCID: 0000-0002-7827-0778 · 3 papers in corpus
article 2024
P-308 Relugolix combination therapy vs relugolix monotherapy with transition to relugolix combination therapy for the treatment of endometriosis-associated pain: implications for cumulative benefit/risk profile
·doi:10.1093/humrep/deae108.273

Abstract Study question How does the benefit/risk profile compare in women with endometriosis-associated pain who initiated relugolix combination therapy (Relugolix-CT) vs relugolix monotherapy with transition to Relugolix-CT? Summary answe…

article 2023
BONE MINERAL DENSITY AFTER TWO YEARS OF TREATMENT WITH RELUGOLIX COMBINATION THERAPY AND ONE-YEAR POST-TREATMENT FOLLOW-UP IN WOMEN WITH ENDOMETRIOSIS: SPIRIT PROGRAM
·doi:10.1016/j.fertnstert.2023.08.234
article 2022
EVALUATION OF THE EFFECT OF RELUGOLIX COMBINATION THERAPY ON BONE MINERAL DENSITY (BMD) OVER TWO YEARS IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: SPIRIT LONG-TERM EXTENSION (LTE) STUDY
·doi:10.1016/j.fertnstert.2022.08.631